智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300122 智飞生物

已收盘 10-16 15:00:00

{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":12.57,"timestamp":1792134222000,"preClose":12.69,"halted":0,"volume":24354916,"delay":0,"changeRate":-0.0095,"floatShares":1414000000,"shares":2394000000,"eps":-6.2385,"marketStatus":"已收盘","change":-0.12,"latestTime":"10-16 15:00:00","open":12.8,"high":13.08,"low":12.52,"amount":312000000,"amplitude":0.0441,"askPrice":12.58,"askSize":200,"bidPrice":12.57,"bidSize":46,"shortable":0,"etf":0,"ttmEps":-6.2385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792373400000},"marketStatusCode":5,"adr":0,"adjPreClose":12.69,"symbolType":"stock","openAndCloseTimeList":[[1792114200000,1792121400000],[1792126800000,1792134000000]],"highLimit":13.96,"lowLimit":11.42,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":2.02,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":-0.123799,"marketValue":30090000000,"turnoverRate":0.0172,"status":1,"floatMarketCap":17778000000},"requestUrl":"/m/hq/s/300122/","defaultTab":"news","newsList":[{"id":"2675989425","title":"智飞生物：专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2675989425","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675989425?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:33","pubTimestamp":1792143205,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司维持上市公司的目的和意义是什么？智飞生物回复：您好，公司专一、专注、专业地在生物制药领域深耕，聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600030035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0188","BK1610","BK0046","03069","BK0239","LU1064130708.USD","300122","BK0196","LU2580892862.HKD","LU2580892789.USD","LU1064131003.USD","LU1328615791.USD","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675989435","title":"智飞生物：重庆宸安聚焦糖尿病、肥胖等代谢类疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2675989435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675989435?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:30","pubTimestamp":1792143042,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)10月16日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司目前在创新药方面在研的管线有多少？涉及什么方向的？智飞生物回复：您好，公司通过北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地持续完善“预防&治疗”一体化布局。重庆宸安聚焦糖尿病、肥胖等代谢类疾病领域，围绕GLP-1类似物、胰岛素类似物等领域布局。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。公司的研发管线详情请您查阅公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600029841.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","300122","BK0239","LU1064131003.USD","BK0077","BK0196","LU1064130708.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675560739","title":"智飞生物最新公告：首次回购公司股份78.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2675560739","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675560739?lang=zh_cn&edition=full","pubTime":"2026-10-16 17:21","pubTimestamp":1792142482,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司于2026年7月20日审议通过回购方案，拟以自有或自筹资金回购股份用于股权激励或员工持股计划，回购金额不低于1.5亿元且不超过3亿元，回购价格不超18.22元/股。2026年10月16日，公司首次通过集中竞价方式回购股份78.28万股，占总股本0.0327%，成交总金额999.91万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600029199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU1064130708.USD","300122","BK0046","LU1064131003.USD","LU2580892862.HKD","BK0188","LU2580892789.USD","LU1328615791.USD","BK0239","BK0196","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675551471","title":"智飞生物（300122）10月15日主力资金净卖出1495.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675551471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675551471?lang=zh_cn&edition=full","pubTime":"2026-10-16 09:09","pubTimestamp":1792112968,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月15日收盘，智飞生物报收于12.69元，下跌0.47%，换手率1.74%，成交量24.54万手，成交额3.12亿元。10月15日的资金流向数据方面，主力资金净流出1495.06万元，占总成交额4.78%，游资资金净流入186.83万元，占总成交额0.6%，散户资金净流入1308.23万元，占总成交额4.19%。融券方面，融券卖出2900.0股，融券偿还1.42万股，融券余量20.57万股，融券余额261.1万元。智飞生物主营业务：疫苗、生物制品研发、生产、销售、配送及进出口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101600008792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1328615791.USD","LU1064131003.USD","BK0196","BK0046","BK0077","LU2580892789.USD","BK0239","LU2148510915.USD","BK0188","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675999493","title":"智飞生物（300122）10月13日主力资金净卖出3395.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675999493","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675999493?lang=zh_cn&edition=full","pubTime":"2026-10-14 09:16","pubTimestamp":1791940608,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，智飞生物报收于13.01元，下跌2.03%，换手率1.86%，成交量26.29万手，成交额3.42亿元。10月13日的资金流向数据方面，主力资金净流出3395.72万元，占总成交额9.92%，游资资金净流入3018.7万元，占总成交额8.82%，散户资金净流入377.02万元，占总成交额1.1%。融券方面，融券卖出7000.0股，融券偿还5200.0股，融券余量21.88万股，融券余额284.59万元。智飞生物主营业务：疫苗、生物制品研发、生产、销售、配送及进出口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400008445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","BK0196","BK0077","LU2148510915.USD","LU1064131003.USD","300122","LU1064130708.USD","BK0046","LU2580892789.USD","BK0239","LU1328615791.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674845705","title":"股市必读：智飞生物新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674845705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674845705?lang=zh_cn&edition=full","pubTime":"2026-10-12 02:55","pubTimestamp":1791744911,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，智飞生物报收于13.7元，上涨0.81%，换手率2.61%，成交量36.98万手，成交额4.98亿元。当日关注点交易信息汇总：10月9日主力资金净流出563.17万元，占总成交额1.13%。公司公告汇总：截至2026年9月30日，智飞生物尚未实施于2026年7月20日董事会审议通过的股份回购计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1328615791.USD","LU1064131003.USD","BK0077","LU2148510915.USD","LU2580892789.USD","BK0046","BK0188","BK0239","300122","BK0196","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674485046","title":"智飞生物（300122）披露关于回购公司股份的进展公告，10月09日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674485046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674485046?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:31","pubTimestamp":1791556275,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘，智飞生物报收于13.7元，较前一交易日上涨0.81%，最新总市值为327.95亿元。该股当日开盘13.58元，最高13.76元，最低13.14元，成交额达4.98亿元，换手率为2.61%。智飞生物于近日披露《关于回购公司股份的进展公告》。公告显示，公司于2026年7月20日召开第六届董事会第十二次会议，审议通过《关于回购公司股份方案的议案》，拟使用自有资金或自筹资金以集中竞价交易方式回购公司A股股份，用于股权激励或员工持股计划。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","LU1064131003.USD","LU2580892789.USD","BK0077","BK0196","BK0188","BK0046","LU2580892862.HKD","BK0239","LU2148510915.USD","LU1064130708.USD","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673492860","title":"智飞生物（300122）9月30日主力资金净买入7710.43万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673492860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673492860?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:02","pubTimestamp":1791421349,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，智飞生物报收于13.98元，上涨6.88%，换手率5.08%，成交量71.87万手，成交额9.88亿元。9月30日的资金流向数据方面，主力资金净流入7710.43万元，占总成交额7.81%，游资资金净流入4228.46万元，占总成交额4.28%，散户资金净流出1.19亿元，占总成交额12.09%。融券方面，融券卖出8500.0股，融券偿还2.48万股，融券余量21.07万股，融券余额294.63万元。智飞生物主营业务：疫苗、生物制品研发、生产、销售、配送及进出口。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2580892862.HKD","LU2148510915.USD","BK0239","LU1064130708.USD","300122","BK0077","LU2580892789.USD","LU1328615791.USD","BK0188","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671747312","title":"9月30日智飞生物涨6.88%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671747312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671747312?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:38","pubTimestamp":1790757520,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日智飞生物涨6.88%，收盘报13.98元，换手率5.08%，成交量71.87万手，成交额9.88亿元。重仓智飞生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.13亿元，最新净值0.6586，较上一交易日上涨0.11%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562860","BK0046","LU1328615791.USD","BK0188","LU1064130708.USD","BK0239","LU2580892789.USD","LU1064131003.USD","LU2580892862.HKD","BK0077","300122","LU2148510915.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669627482","title":"智飞生物：9月23日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669627482","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669627482?lang=zh_cn&edition=full","pubTime":"2026-09-23 23:01","pubTimestamp":1790175694,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月23日智飞生物发布公告称公司于2026年9月23日召开业绩说明会。相关调整对公司经营业绩的影响，以公司披露的定期报告为准。公司旗下宸安生物研发的利拉鲁肽注射液于今年 7月获批上市，9月正式发货并完成全国首针注射，已投入临床使用。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300041674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","BK0046","LU1064130708.USD","BK0196","BK0077","300122","LU2580892789.USD","LU2580892862.HKD","LU2148510915.USD","BK0239","BK0188","LU1328615791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668185766","title":"智飞生物：截至2026年9月18日，公司普通股股东人数为122,538","url":"https://stock-news.laohu8.com/highlight/detail?id=2668185766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668185766?lang=zh_cn&edition=full","pubTime":"2026-09-20 17:24","pubTimestamp":1789896245,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问截至2026年9月15日，公司普通股股东人数是多少？谢谢。智飞生物回复：您好，截至2026年9月18日，公司普通股股东人数为122,538，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000007299.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","BK0046","LU1064131003.USD","LU1328615791.USD","LU2148510915.USD","LU2580892789.USD","BK0188","BK0239","300122","BK0196","LU1064130708.USD","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540384","title":"智飞生物：专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540384?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:57","pubTimestamp":1789117034,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，现在投资者很多都已经盼望智飞生物直接退市，本金早已经亏损完了，对公司发展更不抱有任何希望。公司针对这一现实情况，公司的市值管理计划是怎样实施的？效果怎样？请详细回答一下，谢谢。智飞生物回复：您好，公司专一、专注、专业地在生物制药领域深耕，聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2580892862.HKD","LU1064131003.USD","LU1328615791.USD","BK0239","BK0196","LU2148510915.USD","300122","BK0077","03069","BK0188","LU2580892789.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540877","title":"智飞生物：公司持续践行国际化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540877?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:57","pubTimestamp":1789117030,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，印度本土药企曼凯制药于8月20日宣布，已与重庆宸安生物制药有限公司达成独家进口授权协议，将在印度市场商业化推广该公司德谷胰岛素以及德谷胰岛素与门冬胰岛素复方制剂，用于治疗1型、2型糖尿病，意在强化曼凯制药在糖尿病，是否属实？公司为何不公布公开？请详细解释一下智飞生物回复：您好，公司持续践行国际化战略，推动自有产品海外市场拓展步伐。公司产品的国际化进展情况请您持续关注公司的信息披露，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","LU2148510915.USD","BK0239","BK0077","BK0188","LU2580892862.HKD","LU2580892789.USD","LU1328615791.USD","LU1064131003.USD","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326943","title":"智飞生物(300122.SZ)：司美格鲁肽注射液申请生产注册获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326943","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665326943?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:10","pubTimestamp":1788858625,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日获悉，由公司控股子公司重庆宸安生物制药有限公司研发的司美格鲁肽注射液申请生产注册获得国家药品监督管理局出具的《受理通知书》。该产品Ⅲ期临床研究数据表明，宸安生物研发的司美格鲁肽注射液与原研产品诺和泰临床疗效和安全性相当。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：司美格鲁肽注射液申请生产注册获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892862.HKD","BK0196","BK0077","LU2148510915.USD","LU1064131003.USD","300122","LU1064130708.USD","BK0046","LU2580892789.USD","BK0239","LU1328615791.USD","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665931105","title":"智飞生物最新公告：重组轮状病毒亚单位疫苗获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665931105","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665931105?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:44","pubTimestamp":1788774283,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司全资子公司智飞绿竹研发的重组轮状病毒亚单位疫苗(大肠杆菌)获国家药监局临床试验批准，同意开展预防轮状病毒感染引起的急性胃肠炎的临床试验。该疫苗覆盖全球流行毒株谱系广、安全性高，采用注射途径免疫，具有免疫原性更稳定、持久、接种窗口期更长的特点。若进展顺利，将进一步丰富公司消化道传播疫苗矩阵，完善产品布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","LU1064131003.USD","LU2148510915.USD","BK0239","BK0077","BK0188","LU2580892862.HKD","LU2580892789.USD","LU1328615791.USD","159646","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380706","title":"智飞生物：默沙东将供应九价HPV疫苗等三款协议产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664380706?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:51","pubTimestamp":1788511873,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问公司是否还是默沙东的独家代理？是否会代理默沙东的产品？智飞生物回复：您好，公司于2026年4月2日发布《关于与默沙东调整战略合作协议的公告》（2026-20），默沙东将按照协议规定，向公司供应或安排供应九价HPV疫苗（佳达修9）、五价轮状病毒疫苗（乐儿德）、23价肺炎多糖疫苗（纽莫法）三款协议产品。详情请查阅公司在巨潮资讯网披露的公告，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1328615791.USD","LU1064131003.USD","BK0077","LU2148510915.USD","LU2580892789.USD","BK0046","BK0188","BK0239","159646","300122","BK0196","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802483","title":"智飞生物：公司有序推进23价肺炎球菌多糖疫苗在海外的上市注册工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802483","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664802483?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511693,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：公司疫苗产品海外注册、海外市场拓展的最新进展，目前哪些产品已经启动境外申报？智飞生物回复：您好，公司持续践行国际化战略，加快自有产品海外市场拓展步伐。公司有序推进23价肺炎球菌多糖疫苗在海外的上市注册工作；结核诊断产品宜卡（EC）已在泰国等结核病高负担国家启动注册程序。公司国际化进展情况请您持续关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","159646","LU2148510915.USD","BK0196","LU1328615791.USD","BK0239","300122","BK0046","LU2580892789.USD","LU1064131003.USD","LU1064130708.USD","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664299380","title":"智飞生物：自主在研项目共42项","url":"https://stock-news.laohu8.com/highlight/detail?id=2664299380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664299380?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511691,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司从疫苗代理到现在的自研疫苗治疗药物双轮驱动，请问具体有哪些新产品？什么时候上市？最近公司有什么利好的事情导致股价突然上涨？智飞生物回复：您好，公司持续开展产品创新，目前自主在研项目共42项，其中处于申报、开展临床试验及申请注册阶段的预防类在研项目29项,已进入不同临床阶段的重点治疗类在研项目 5 项。公司在研管线详情请您关注查阅公司的信息披露，感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0077","LU2580892789.USD","BK0239","BK0046","BK0188","LU1064131003.USD","LU2148510915.USD","300122","LU1328615791.USD","LU2580892862.HKD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245380","title":"智飞生物：公司在售产品有重组带状疱疹疫苗（CHO细胞）","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664245380?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:48","pubTimestamp":1788511691,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月04日在投资者关系平台上答复投资者关心的问题。投资者提问：带状疱疹疫苗最近有什么利好消息吗？智飞生物回复：您好，公司在售产品有重组带状疱疹疫苗（CHO细胞），中文商品名：欣安立适。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400029338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","LU1064131003.USD","LU2148510915.USD","BK0239","BK0077","BK0188","LU2580892862.HKD","LU2580892789.USD","LU1328615791.USD","159646","BK0196","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879773","title":"智飞生物(300122.SZ)：流感病毒裂解疫苗药品补充申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879773","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879773?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:07","pubTimestamp":1788509243,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智飞生物 发布公告，公司于近日收到全资子公司安徽智飞龙科马生物制药有限公司报告，由智飞龙科马自主研发的流感病毒裂解疫苗药品补充申请获得国家药品监督管理局出具的《受理通知书》。智飞龙科马的流感病毒裂解疫苗已于2025年9月获批上市，适用于3岁及以上人群预防流感病毒引起的感染性疾病。本次补充申请为流感病毒裂解疫苗在已经获得注册批准的适用人群基础上增加“6-35月龄儿童”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492044.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智飞生物(300122.SZ)：流感病毒裂解疫苗药品补充申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","BK0196","LU1328615791.USD","LU2580892862.HKD","159646","LU1064131003.USD","300122","BK0077","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792181960695,"stockEarnings":[{"period":"1week","weight":-0.0825},{"period":"1month","weight":0.0195},{"period":"3month","weight":0.0244},{"period":"6month","weight":-0.1875},{"period":"1year","weight":-0.3889},{"period":"ytd","weight":-0.3339}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0127},{"period":"6month","weight":-0.0827},{"period":"1year","weight":-0.0511},{"period":"ytd","weight":-0.0636}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"123196人(较上一季度增加0.54%)","perCapita":"11480股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":"　　重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、流感病毒裂解疫苗、达舒宸、佳达修9、乐儿德、纽莫法、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}